help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_1, 14-20, January 2008; doi:10.1634/theoncologist.13-S1-14
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Marinis, F.
Right arrow Articles by Grossi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Marinis, F.
Right arrow Articles by Grossi, F.

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer

Filippo de Marinisa, Francesco Grossib

aThoracic Oncology Unit I, Department of Lung Diseases, San Camillo and Forlanini Hospitals, Rome, Italy; bMedical Oncology A, Disease Management Team – Lung Cancer, National Institute for Cancer Research, Genova, Italy

Key Words. NSCLC • Second-line chemotherapy • Pemetrexed • Docetaxel • Erlotinib

Correspondence: Filippo de Marinis, M.D., Thoracic Oncology Unit I, Chief Carlo Forlanini Hospital, Pza Forlanini 1, 00151, Rome, Italy. Telephone: 39-06-5555-2565; Fax: 39-06-5555-2565; e-mail: demarinis.filippo{at}virgilio.it

Disclosure: F.d.M. has acted as a consultant to Eli Lilly and Company, Roche, and Sanofi-Aventis, and has received honoraria from Pierre Fabre, Amgen, and GlaxoSmithKline. F.G. has acted as a consultant to Eli Lilly and Company, GlaxoSmithKline, and Roche, and has received honoraria from Sanofi-Aventis.

In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.




This article has been cited by other articles:


Home page
 ChestHome page
D. Tassinari, E. Scarpi, S. Sartori, E. Tamburini, C. Santelmo, P. Tombesi, and L. Lazzari-Agli
Second-Line Treatments in Non-small Cell Lung Cancer: A Systematic Review of Literature and Metaanalysis of Randomized Clinical Trials
Chest, June 1, 2009; 135(6): 1596 - 1609.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J.-M. Sun, K.-W. Lee, J. H. Kim, Y. J. Kim, H. I. Yoon, J.-H. Lee, C.-T. Lee, and J. S. Lee
Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 27 - 32.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.